Clinical Trials Logo

Renal Cell Carcinoma clinical trials

View clinical trials related to Renal Cell Carcinoma.

Filter by:

NCT ID: NCT03024996 Terminated - Clinical trials for Renal Cell Carcinoma

A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy

IMmotion010
Start date: January 3, 2017
Phase: Phase 3
Study type: Interventional

This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.

NCT ID: NCT02989714 Completed - Clinical trials for Renal Cell Carcinoma

Phase Ib/II Trial of Interleukin-2 and PD-1 Checkpoint Inhibitor, Nivolumab In Metastatic Clear Cell Renal Cell Cancer

Start date: March 16, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This will be a single arm, multi-site phase Ib/II clinical trial of standard doses of High Dose Interleukin-2 (HD IL2) (600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart) in IL-2 eligible clear cell metastatic RCC (Renal Cell Carcinoma) subjects in combination with Nivolumab. Investigators hypothesize that concurrent PD-1 inhibition synergistically enhances the anti-tumor immune response to HD IL-2 in metastatic clear cell RCC. Investigators postulate that the combination of the two therapies would result in an increase in the overall response rate, complete response rate, and improved survival outcomes compared to either of the individual therapies.

NCT ID: NCT02983045 Completed - Gastric Cancer Clinical Trials

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors

PIVOT-02
Start date: December 19, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D. Part 2 considered dose expansion cohorts for the doublet (NKTR 214 + nivolumab ± chemotherapy). Part 3 was schedule-finding for a triplet therapy (NKTR 214 + nivolumab + ipilimumab). Part 4 dose expansion for the triplet (NKTR 214 + nivolumab + ipilimumab) was planned to further assess the efficacy of the RP2D triplet combination at dosing schedules from Part 3.

NCT ID: NCT02982954 Completed - Clinical trials for Renal Cell Carcinoma

A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer

CHECKMATE 920
Start date: January 16, 2017
Phase: Phase 4
Study type: Interventional

To investigate the safety of Nivolumab in combination with Ipilimumab in subjects with previously untreated advanced or metastatic Renal Cell Cancer.

NCT ID: NCT02947152 Terminated - Clinical trials for Renal Cell Carcinoma

HKT288 in Solid Tumors, Including Epithelial Ovarian Cancer and Renal Cell Carcinoma

Start date: December 1, 2016
Phase: Phase 1
Study type: Interventional

A first-in-human study using HKT288 in solid tumors, including epithelial ovarian cancer and renal cell carcinoma

NCT ID: NCT02940639 Active, not recruiting - Clinical trials for Renal Cell Carcinoma

Real-Life Effectiveness and Safety in Participants With Advanced/Metastatic Renal Cell Carcinoma Starting 1st Line Nivolumab and Ipilimumab Combination Therapy or Nivolumab Monotherapy After Prior Therapy

Start date: October 27, 2016
Phase:
Study type: Observational

The purpose of this study is to estimate overall survival over a 5-year follow-up period among adult participants with advanced/metastatic kidney cancer, starting 1st line nivolumab and ipilimumab combination therapy or nivolumab monotherapy after prior therapy, in real-life conditions in Germany

NCT ID: NCT02928263 Withdrawn - Clinical trials for Renal Cell Carcinoma

Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents

Start date: February 28, 2017
Phase: N/A
Study type: Observational

A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents

NCT ID: NCT02924597 Recruiting - Clinical trials for Renal Cell Carcinoma

Robot-Assisted Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage

Start date: January 2016
Phase: N/A
Study type: Interventional

To evaluate the feasibility and efficiency of zero ischemia robot-assisted laparoscopic radio frequency ablation assisted enucleation of T1a renal cell carcinoma in comparison with robot-assisted laparoscopic partial nephrectomy without hilar clamping.

NCT ID: NCT02923284 Completed - Clinical trials for Renal Cell Carcinoma

NANOTECH RCC Biomarkers

Start date: August 2016
Phase:
Study type: Observational

The incidence of renal cell carcinoma (RCC or kidney cancer) in men exceeds that of pancreatic cancer or leukemia. In women, the incidence of RCC is similar to that of leukemia, ovarian, or pancreatic cancer; thus, RCC is significant health issue. This study focuses on identifying specific molecules [biomarkers] of RCC that can be used to develop a reliable low-cost screening method at the point of service. If successful, our method would provide a diagnostic test to distinguish benign kidney masses from malignant ones, eliminating the need to surgically remove a kidney with a benign tumor.

NCT ID: NCT02919371 Recruiting - Clinical trials for Renal Cell Carcinoma

Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)

Start date: December 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Combined sunitinib and bevacizumab in advanced renal cell carcinoma.